Environmental

Amgen’s high R&D intensity supports a lower-carbon, science-based operating model versus peers that rely more heavily on manufacturing scale and commodity inputs.

The company’s biologics-focused portfolio generally reduces direct emissions intensity relative to many large-cap healthcare peers, although specialized production still carries energy and waste burdens.

Capital allocation toward research rather than asset-heavy expansion can limit incremental environmental footprint versus peers with larger physical manufacturing buildouts.

Environmental disclosure is less differentiated than best-in-class peers, so the position appears solid rather than leading on climate, water, and waste management transparency.

Social

Amgen’s heavy R&D spend indicates sustained investment in medicines and patient outcomes, which is a stronger social signal than peers with lower innovation intensity.

The company’s low stock-based compensation burden suggests comparatively restrained dilution and may support a more balanced employee-value proposition than peers with more aggressive equity pay.

As a major biopharma company, product quality, access, and pharmacovigilance remain material social risks, but these are broadly managed in line with large-cap industry norms.

Relative to peers, Amgen appears stronger on workforce and innovation commitment, though it is not clearly differentiated by public evidence on access or community impact.

Governance

Amgen’s leverage is elevated versus many large-cap healthcare peers, which increases governance sensitivity around capital discipline and balance-sheet oversight.

The company’s modest stock-based compensation as a share of revenue is a positive governance signal versus peers that rely more heavily on equity-linked pay.

High R&D intensity requires disciplined portfolio governance, and execution risk is material because misallocation can impair long-term stakeholder trust versus peers.

Overall governance appears acceptable but not top-tier, because balance-sheet leverage and capital allocation discipline remain more important than any single positive compensation metric.

Overall Score

Amgen’s ESG profile is strongest on social and environmental fundamentals, while governance is held back by comparatively elevated leverage and capital-discipline sensitivity.

Score Driver: High R&D Intensity And Biologics-Based Operating Model Versus Peers